It plainly is, according to AMGN’s PR in #msg-65277106:
Regarding Neugranin™, another Teva G-CSF product, Teva agrees not to sell Neugranin until Nov. 10, 2013 unless it first obtains a final court decision that Amgen's patents are not infringed by Neugranin.
Neugranin is a knockoff of Neulasta.
I did misspeak in my prior post, however, by saying that Teva picked up Neugranin in the Ratiopharm acquisition; in fact, Teva got Neugranin from CoGenesys, the spin-off from HGSI that Teva bought in 2008 (#msg-26163282). In the Ratiopharm deal, Teva acquired a Neupogen FoB called Ratiograstim that was already being marketed in Europe, where it competed with TevaGrastim (another name for Neutroval); Ratiograstim will not be developed for the US because there is no benefit to Teva from having two Neupogen FoB’s in that market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.